Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Ryan. CC is going to be awesome. I have no doubt. So many questions though.
Is it just Oxy?
Update on once daily in Europe?
Lodrane 24 replacement update
Patents pending
Next drug launches
Next Drug approvals
Some simple math tells you this is already a profitable drug company and rapidly growing pipeline and revenues if you take away the ART program. Of course you would never do that because that is billions but it is impressive nonetheless.
A couple more notes about the filing
83% increase YOY
They now have a ton of cash to move forward. It would seem to be for several trials, or several products actually
CC on Monday should be huge
$1.9m in inventory. Between the MS payment and this, I believe you are looking at a $2m quarter next quarter and rapidly growing
http://online.wsj.com/article/PR-CO-20131114-913833.html?dsk=y
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2014
Revenues Increase by 83%, Product Development Accelerating
Conference Call Scheduled for Monday, November 18 at 3:00 PM ET
NORTHVALE, N.J., Nov. 14, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the second quarter of fiscal year 2014 ended September 30, 2013.
Total revenues for the quarter ended September 30, 2013 were $1.2 million, an increase of 83% from the prior year. This growth is attributed to the recent launch of 3 new products, Naltrexone 50mg in the September quarter and Phentermine 15mg and 30mg capsules in the June quarter, combined with strong year-on-year growth of Elite's Phentermine 37.5mg tablets, Hydromorphone 8mg tablets and contract manufactured Methadone 10mg product lines.
Consolidated quarterly loss from operations was $0.7 million, and GAAP net income, including non-cash income related to the accounting treatment of preferred share and warrant derivatives was a net loss of $9.6 million. Basic and diluted loss per share was $(0.02) on a weighted average 422.0 million common shares outstanding. Elite's operations incurred a $1.3 million negative cash flow for the six months ended September 30, 2013, due in large part to the cost of significantly expanded product development activities.
Subsequent to the end of the quarter, Elite executed a manufacturing and license agreement with Epic Pharma LLC, wherein Elite grants manufacturing and distribution rights to Epic in relation to the 12 approved ANDA's acquired by Elite in August 2013. Epic will have exclusive licenses to 6 of these approved ANDA's and non-exclusive licenses to the remaining 6 approved ANDA's. Pursuant to this agreement, Elite will receive various milestone payments and profit splits from sales of these products. Elite expects this agreement to begin generating revenues during the quarter ended December 31, 2013.
"In addition to launching a new product and substantially increasing our revenues, we have set in motion several initiatives that will have significant impact on Elite's future," commented Nasrat Hakim, President and CEO of Elite. "During this quarter, we acquired 12 new approved products, greatly accelerated the development of our abuse resistant technology and are on schedule for clinical trials to begin this year."
The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Monday, November 18, 2013 at 3:00 PM ET. Company executives will also conduct a question and answer session following their remarks. To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until December 2, 2013 by dialing:
Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840
The financial statements can be viewed in Elite's Quarterly Report on Form 10-Q at: http://www.elitepharma.com/sec_filings.asp.
What a Great Report and a huge CC on Monday.
http://online.wsj.com/article/PR-CO-20131114-913833.html?dsk=y
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2014
Revenues Increase by 83%, Product Development Accelerating
Conference Call Scheduled for Monday, November 18 at 3:00 PM ET
NORTHVALE, N.J., Nov. 14, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the second quarter of fiscal year 2014 ended September 30, 2013.
Total revenues for the quarter ended September 30, 2013 were $1.2 million, an increase of 83% from the prior year. This growth is attributed to the recent launch of 3 new products, Naltrexone 50mg in the September quarter and Phentermine 15mg and 30mg capsules in the June quarter, combined with strong year-on-year growth of Elite's Phentermine 37.5mg tablets, Hydromorphone 8mg tablets and contract manufactured Methadone 10mg product lines.
Consolidated quarterly loss from operations was $0.7 million, and GAAP net income, including non-cash income related to the accounting treatment of preferred share and warrant derivatives was a net loss of $9.6 million. Basic and diluted loss per share was $(0.02) on a weighted average 422.0 million common shares outstanding. Elite's operations incurred a $1.3 million negative cash flow for the six months ended September 30, 2013, due in large part to the cost of significantly expanded product development activities.
Subsequent to the end of the quarter, Elite executed a manufacturing and license agreement with Epic Pharma LLC, wherein Elite grants manufacturing and distribution rights to Epic in relation to the 12 approved ANDA's acquired by Elite in August 2013. Epic will have exclusive licenses to 6 of these approved ANDA's and non-exclusive licenses to the remaining 6 approved ANDA's. Pursuant to this agreement, Elite will receive various milestone payments and profit splits from sales of these products. Elite expects this agreement to begin generating revenues during the quarter ended December 31, 2013.
"In addition to launching a new product and substantially increasing our revenues, we have set in motion several initiatives that will have significant impact on Elite's future," commented Nasrat Hakim, President and CEO of Elite. "During this quarter, we acquired 12 new approved products, greatly accelerated the development of our abuse resistant technology and are on schedule for clinical trials to begin this year."
The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Monday, November 18, 2013 at 3:00 PM ET. Company executives will also conduct a question and answer session following their remarks. To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until December 2, 2013 by dialing:
Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840
The financial statements can be viewed in Elite's Quarterly Report on Form 10-Q at: http://www.elitepharma.com/sec_filings.asp.
What does that mean? I am still trying to understand this. This is a most peculiar stock with high upside obviously and going to be a traders dream for awhile if that is your game.
I still find it peculiar how news for TDEY related to IPOINT TV does not show up on my trading platform. It will mention the stock symbol and the company but it doesn't hit my platform.
It would almost seem like someone does not want the company to get the publicity.
Keep your eye on short volume but it means little to me until you see well above 50% numbers. Watch the MMs too. You can begin to figure out which ones are naked shorting to cover orders. Means little really.
I am sure people are willing to short these stocks but it is probably not that common and perhaps more of an intraday thing. Risk Reward is just not there due to the cost, liquidity and risk.
Just my .02
Ok what is missing from he filings, you have my interest.
Thanks. It should be a no brainer for anyone traveling overseas. For a few bucks your family can reach you anytime for minimal cost. Think about sending your kids on an exchange program, family going over etc....
Very odd that people would continue to present misinformation after they note the conference call where they can hear what was actually said or read the transcript. Trials are be initiated and plan to submit results to FDA in 6 months for the twice a day Oxycontin product.
From the transcript from 6 weeks ago. I suspect we will get an announcement here shortly. This is just one of a bunch of items I am expecting from the company this year.
"Well, our next step is to capitalize on that, as for our clinical trials. We are initiating clinical trial within the next two to three months, okay on our twice-a-day. As I said earlier, we have already conducted a study on 19 subjects on the once-a-day and the results were phenomenal. So, we are going for the twice-a-day right now on a full subject.
And we will decide the next step after that. We are hoping as per our communication with the FDA that we will go through three stages or three things over the next six months before we finally are ready to submit our ANDA for approval."
I have an idea I want to pass on to the CEO. I may call him again, but if you guys talk to him here is something they should be considering.
The value and revenue drivers for this company is in the long distance imo. I used to travel overseas for work and calling home was always problematic.
However now with this app, people that travel for work can use their same phone (we had iphones) download the app and for minimal cost compared to what it would normally cost. We used Skype from the hotel rooms and our laptops.
He should be advertising with websites like Travelocity, Expedia, Orbitz, the Shatner one etc.....
Even could be an add on cost when you are checking out from ordering your trip.
Also sell it through travel agents. It would be an easy sell and give everyone a cut for the sales.
Give people the peace of mind that their family can reach them anytime on their trip just like they normally would without worry of the costs.
A couple notes,
Be skeptical of Finra shorting numbers. I am not saying it is naked shorting, MMs or just people shorting the stock. My experience is that most of the time it is traders selling into the bid and trying to maneuver into position and create sellers, hold the price down, frustrate longs.
I like this App and it has a lot of possibilities, just need the revenues
Anyone know why news does not shop up for SWRF on my trading platforms but it does for TDEY?
From a market cap perspective which I have preached here in the past, Elite has 20 approved drugs. 20 more in the pipeline. Any comparison to a similar company and you have to look at two companies and add them or extrapolate. Either way you end up with market caps in the 100s of millions.
However with this Epic deal, what has transpired is that Elite made themselves extremely profitable from Operations. It was a brilliant move.
Epic has a huge facility and this relationship with Mikah is not fully understood yet. These products are very valuable....much more then the 10m bucks obviously.....I am saving some of this info for later but people should dig deeper. A lot more going on then we realize.
Yeah watching the bid and ask, you can almost smell the attempts to shake people out. Reading the board today, I barely see anyone discussing the trials, outcomes, various products, all the pending transfers, pending approvals etc, patents.....
Most twelve cent stocks would have people focused squarely on these any one of these items. Kind of like poster couch noted how mgmt. said they are kind of surprised the market hasn't caught on yet...
But there are forces willing to do whatever they can to hold the price down and manipulate others. It is amazing what you can figure out watching trading and doing your DD.
Why all the focus on the run up in 2011. The company was going out of business and there were very few shares that were actually sold at .26. You can still check the charts you know?
However you can see how explosive this company and this market can be. Trials on the $2.7B market will be fun.
Do you think they will announce the CRO for these studies here shortly? Maybe let it fly on the CC.
Also since there are partners already interested, I am starting to think that there is a lot more going on for these trials then simply the sake of FDA approvals. These guys will sell this company for big bucks. That is the most likely, and logical conclusion and the reason someone like Nasrat Hakim buys 11m shares and takes over the company.
Interesting run up here. We saw how thin it was before but it got pushed down and here we are again but I don't think it is coming back down. It does seem tied to TDEY but should have a market cap of TDEY x 5 IMO.
Interesting. Almost no short volume. Usually you see some from the MMs like Knight Capital to naked short to cover trades as part of normal day to day.
So what we see here is traders working the bid and ask, steady buying and selling and typical manipulative tactics watching bid and ask....and likely a bunch of accumulation.
The Chart shows the buildup. The last run was based on the addition of 12 FDA approved drugs but this next one should be based on the announcement of the trials for Oxycontin market of $2.7B market.
However there are numerous other items that could step in like pending drug approvals and partnerships pending. Also look for an announcement for the Conference call in a couple weeks. This will be based on these trials. This will be a highly anticipated CC.
I believe in the finance world also discussed by those like the mad money guy on CNBC, Kramer, there are folks hired to try and manipulate others. Kramer has admitted as such. These folks are sometimes overseas so they can skirt the law. ELTP will attract these types because it is extremely undervalued....20 FDA approved drugs, huge R&D, financing, and these folks work to see the stock held down for accumulation, covering a short position(There isn't one here really), competition, etc...
I refer to them as fluffers for a variety of reasons.
Very exciting . Trials starting shortly. 13 more FDA approved drugs. 3 more pending approval. 3 patents.
Multiple ART products. CEO loan to limit the dilutive effect of the 10m financing and accelerate R&D efforts...ie trials about to start as noted.
Partnerships with major pharmas in negotiation.
Rizzo,
If you think about what we learned at the R&R conference and this loan, it becomes obvious that they are not taking anything less then top dollar. Getting these trials going first brings in more money. $1m now, gets you $50m more later.m Remember the value accretion curve.? Good times.
Nasrat has noted the superiority, simplicity of the tech and lets not forget he was involved in other competing techs at Actavis and Alpharma. He came to Elite with a purpose, and a pocketful of shares.
The science here is straightforward as the Chairman likes to say and it is the same concept as Embeda and ALO-02 but far more robust and modular.
Interesting day. Ipoint App should be released here shortly. The CC was a good listen. Good volume today. Looked like the continued shake out. Again, If TDEY is a 1m cap, SWRF should be 5m cap in my opinion anyway.
Did some review of the App online. Lots of Christian channels and international stuff. It is interesting. I like what they are trying to do and finally understanding the concept of going after content.
The PRs are weird though. No real discussion here over this recent one. WOnder what was said at the meetings. Is todays action further shake out. And if TDEY is hot, and its content will be on SWRFs Ipoint, then this should be much much higher but maybe its all a sham but I haven't figured out how yet.
iPoint TV Enters Into Talks with Major Broadcast Networks and TV Stations to Retransmit on its TV Everywhere
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=23055
Poorme, it is pretty much accepted that these type products will be fast tracked at this point. Between societal need, congress and politics, that is trend on these endeavors right now. This point really can't be argued if you take 5 minutes and review the market right now.
Actually his treasury is not enhanced with anything until the money is loaned and held as loan. It is a revolving line of credit and unsecured at that.
Every loan comes with an interest rate.
Are you accusing the CEO of some sort of malfeasance? It was approved by the BOD who are the biggest share holders in the company alongside that same CEO who is obviously incredibly wealthy already.
Today's move was brilliant for the company and shareholders.
How many CEOs do you see giving unsecured loans out when dilutive financing is available?
Let me ask you a question
Find drug companies that have ~40 products in their pipeline
Of the 40, 20 are approved already and many have very limited competition
Trial about to begin for which they have partnered interest from major pharmas and the products and in a market worth over 3 billions dollars again with limited competition
Add in a CEO with incredible experience, knowledge and his own money in the game
You will be looking at companies with 200-300 million dollar market caps.
Do you agree?
Curious, I am watching TDEY, have a little SWRF, watching closely. Did anyone here attend the meet and greet last night?
Some other items not even being discussed in light of the massiveness of the upcoming trial announcements. Any other .12 cent company would be feeding off this
Pending a partner for Lodrane D - we know one is interested and has financial backing
3 drugs pending approval
3 patents pending approval, one is a slam dunk, any time now should get worked out, other two await reviews and responses
CC in about a month. Will probably be the most exciting in the history of the company.
There was something else but it comes to me I will post.
Very exciting day for me today. Having done my DD, it is obvious that today's loan is to fund the trials that should be starting pretty much any time now. They could have diluted using LPC but why do that if you don't have too. CEO says here is 1 million dollars, lets go get this done. No delays, holdups, manipulative trading BS to force shares on the market at currently depressed prices.
The very same CEO and BOD own tons of shares and don't need to see their investments diluted either. They will sell shares to LPC when they can get fair market value.
Also note the language in the PR about products. Remember it is not just twice daily Oxy being worked here. It is once daily ART and non ART for Europe as well as Embeda.
I read the back and forth below but what is missing is that we are looking at numerous products.
I also love how the CEO who is very experienced with numerous techs (came originally from Alpharma - Embeda and ALO-02 techs) flat out says the product is superior.
Those that have looked into it, will come to this conclusion too but he is not shy. He left a 3000 person company, over seeing 25 facilities to lead a 30 man company.
I laugh when I think about him saying how his budget at Actavis was 10x Elites current market cap.
Did anyone here attend the meeting?
Still have a lot of questions and watching TDEYs volume and moves tells me this has to be close behind. A lot of events coming.
Folks should listen to the podcast. The weirdest thing is if TDEY is .004, SWRF should be more like .02....
It doesn't make any sense...
Should get some announcements soon.
I sent an e-mail to several e-mails I found including that one and received no response.
Something smells and it's not me...
I think Swordfish is 100% legit but there are folks claiming to be this and that....
I read first from the supposed CEO that there is no agreement. Then he says there is an agreement but it is not initiated yet as it is pending a specific milestone. Then he states that there is no agreement.
Is an agreement pending some sort of initiation still an agreement? Are the filings fraudulent? I read the 8k. In fact the supposed CEO was pumping the 8k in his message history here....but there is no deal?
Truly the weirdest stuff I have ever seen. So many things going on with this company and the stock is extremely thin. I watched it go from .04 to .09 on tiny amounts of volume. Where are the shares? Where is the volume. Look at the charts, there is never any volume and when there is, the stock moved fast.
Then there is the buyout rumor PRs stuff....
When is the next CC?
Anyone looking for actual facts about current events at the company and what is actually going on.
Read this article
http://seekingalpha.com/article/1688112-elite-pharmaceuticals-call-it-a-comeback-story
And listen to this presentation
http://www.wsw.com/webcast/rrshq23/register.aspx?conf=rrshq23&page=eltp&url=http%3A//www.wsw.com/webcast/rrshq23/eltp/
Good post. There are a handful of competitors for what is about a 10 billion dollar market. Most have failed and the only ones that have passed are questionable. Purdue's can be defeated relatively easily and Embeda may never return to the market because they can't manufacture a stable batch.
Elite is headed into trials here very shortly and because of the tech and the APIs, it is known and accepted science. It is very similar to Embeda in concept but far more of a stable manufacturing process.
Reading the posts today, the one thing that is left out is all of the items actually going on right now.
Do folks realize that the 13 ANDAs represent about 25 products? And that most of these products have little competition? I found several with one generic competitor. The biggest one only has one competitor in total...
Also should hear about the partner for new Lodrane product too.
I am very curious to see what products get approved next as well. There are a few pending. There is a very exciting one from Mikah that if it is what I think it is, will get some attention....keeping that one to myself for now.
Anyway, do your homework kiddies, give their IR a call....
Global VPs don't retire at 51 from overseeing 3000 employees and 25 facilities worldwide, buy 11m shares to become CEO of a small pharma with 30 employees except to make a ton of money....
Also all of Epic converted all their preferred and no one knows why....funny stuff
hahaha The CEO of OMNIVERSE, also the named CEO in the 8k, the same person on this msg board saying there is no deal between Swordfish and OMNIVERSE. Then another poster notes there is no PR about the event and it is fishy. Then the 8K and PR is presented and it is said that this is not what they are saying....
And the CEOs message history here shows no idea what major retail outlets like Amazon, Sears, Radio Shack his own products are being sold?
WTF is going on here....I don't believe anyone but this sure is fascinating...
And the stock has an evaluation of 10x plus the current price as I noted before and is shown in a PR to have Netflix buyout rumors...link also posted....
And an App is due out on Monday....timeframe?
And best as I was able to determine a bunch of other items....
I have never seen anything like this.
I do know that this stock moved from .004 to .009 on about 10m shares. That is what about 5 thousand dollars?....strangest stock I have ever seen...
Anyone looking for actual facts about current events at the company and what is actually going on.
Read this article
http://seekingalpha.com/article/1688112-elite-pharmaceuticals-call-it-a-comeback-story
And listen to this presentation
http://www.wsw.com/webcast/rrshq23/register.aspx?conf=rrshq23&page=eltp&url=http%3A//www.wsw.com/webcast/rrshq23/eltp/
You see the evaluation. I have seen it here before too. I am new to SWRF so the Netflix thing is probably old news to the board but new to me...
As thin as this stock is, it does make you wonder.
I am not interested in pumping anything but something is not adding up at all here.
It doesn't make sense. What you can is see there are folks that have sold into the bid looking to get their shares back. You see that in the trading. There is an obvious desire to keep this stock under the radar. You see how thin it is. It ran to .009 on a few million shares but look at TDEY. It takes 100m shares.
Ever see a .0044 company that has a product you can buy at radio shack? Amazon? Sears?
See the revenue projections?
People talking about TDEY and all the volume but that is just a slice of IPTV which is swordfish....
If TDEY is .004, SWRF should be .04 but really much higher. Take a look at how Ortiz got paid for IPTV. He got paid in SWRF shares and its really not that much. This is how he is going to make his money in the long run.
I have a small position and am adding
Couple items that is bringing in this manipulation
iPoint TV Enters Into Talks with Major Broadcast Networks and TV Stations to Retransmit on its TV Everywhere Platform
http://www.smallcapnetwork.com/iPoint-TV-Enters-Into-Talks-with-Major-Broadcast-Networks-and-TV-Stations-to-Retransmit-on-its-TV-Everywhere-Platform/s/via/18950/article/view/p/mid/1/id/1788/
iPoint app is due Monday I believe too
Have you guys seen this?
NFLX-Netflix rumors of Buyout of SWRF-Swordfish Financial begin to circulate
https://www.prbuzz.com/business-entrepreneur/157238-nflx-netflix-rumors-of-buyout-of-swrf-swordfish-financial-begin-to-circulate.html
Follow the money....People with money, that can easily make money elsewhere...crap ton of money.....lots of games but until someone can show me a company with a market cap not exceeding 200m dollars, and a
a 40 drug pipeline
20 approved drugs
important drug patents
numerous partnerships
R&D trials about to begin on billion dollar products, everything is just noise
I wish. It is too many different things. How is the stock .004? I don't get it. Seems you will need something to connect to the TV at least for awhile. Or hook up to your mobile device. These items exist. boxee box, roku, etc but this is a little different.
Even if it is smaller player and popular in other countries at first. the company should never be .004
I saw that. Reviews are mixed but I am always skeptical of reviews where there is a relatively small sample.
The Ipoint TV is in many devices now. Soon to be an App as I understand it. This thing is borderline ridiculous. I want to buy one try it out...lol
Anyone try it?
Nasrat was a special advisor to Epic prior. This relationship has been ongoing for years. The thing that ties them all together? Lots of shares of Elite Pharma.
You don't leave behind a top level position at Actavis (as noted here, 3000 subordinates, 15 global facilities), acquire a bunch of generic drugs with minimal competition to become the CEO of a 30 man company, buy 11m shares of Elite, get paid in stock for a lower salary except for one reason.....to make a crap ton of money.
That's a scientific term btw. "crap ton"
I saw the financial projections which are huge and bold to give out. Usually companies at .005 will not give out projections.
Also most companies like this don't have $130 products at a major retail electronics store. There are like 5 stores within 5 miles of my house that show this product in stock it seems. Need to remember to stop by one this weekend. That's why I included the link.
We seem to own this company under IPOINT which is under SWRF. I am just beginning to work through this and I listened to the recent podcasts. Seems they will show some revenue for the first time.
It is one of the more fascinating pennies I have seen. It makes no sense at .004
Nope exclusivity....think about what that means. These products are from the Actavis / Watson Divestiture.....
Traders will sell and sometimes short into the bid to drop the price. Also if they think they can buy it back cheaper. They will do what they can to get you to sell.
Some market makers are known to short more then others but as understand it, they are usually even by the end of the day. Meaning, they short your buy with one hand because they have shares in the other. Nite seems to do this quite a bit.
In these low volume penny stocks, it doesn't take much to try and manipulate and drop the price. Usually accompanied by FUD in the trading or elsewhere, negative articles or other media ways to convince you how bad the company is.
Doesn't make a lot of sense to short these companies for long periods of time. expensive and risky.
So when you see the bids getting hit, it can be shorts, or sellers but often you are just watching traders trying to get others to sell so they can buy cheaper and then run it back up....
PVSP has a big opportunity here with the international VOIP calling and imo the best app out there.